Clinical Trials and Immune Response - Clinical Research Informer

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

BioPharma Reporter

OCTOBER 11, 2022

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

Immune Response

Immune Response Vaccination Vaccine Clinical Trials

Trim the sugar: New HIV vaccine design improves immune response

Medical Xpress

APRIL 20, 2023

A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.

Immune Response

Immune Response Vaccination Vaccine Clinical Trials

Grand Rounds April 14, 2023: RECOVER in Action – Status of Clinical Trial Protocols (Kanecia Zimmerman, PhD, MD, MPH)

Rethinking Clinical Trials

APRIL 18, 2023

There are many hypothesized causes that may co-exist in the same patient, such as persistent virus or antigens, reactivation of other viruses, uncontrolled immune responses, damage to a wide range of organs and tissues, and injury to blood vessels and abnormal blood clotting. It’s all over the place.

Clinical Trials

Clinical Trials Clinical Trials Trials Immune Response

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response

Immune Response Protein Clinical Trials Clinical Trials

Clinical Trials for Celiac Disease: Insights from Beyond Celiac’s Kate Avery

XTalks

MAY 4, 2023

However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. Some of the approaches being studied include: Enzyme therapy: Researchers are testing enzymes that may help break down gluten in the digestive system, reducing the risk of immune system activation and damage to the small intestine.

Clinical Trials

Clinical Trials Clinical Trials Trials Immune Response

Temperature-stable tuberculosis vaccine safe, prompts immune response in first-in-human trial

Medical Xpress

MARCH 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. Results are published in Nature Communications.

Immune Response

Immune Response Vaccination Vaccine Trials

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The post Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response appeared first on.

Immune Response

Immune Response Vaccination Vaccine Trials

UK partners with BioNTech on clinical trials of mRNA cancer therapies

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.

Clinical Trials

Clinical Trials Clinical Trials Trials Vaccination

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response

Immune Response Vaccine Vaccination Antibody

China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). This blocks a cascade of responses that are induced by interleukin-25 (IL-25), a critical cytokine which is classified as ‘alarmin’.

Immune Response

Immune Response Clinical Trials Clinical Trials Antibody

Medicago Says COVID-19 Vaccine Candidate Triggers Promising Immune Response | 2020-11-10

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Martin Berman-Gorvine. Source link.

Immune Response

Immune Response Vaccination Vaccine Clinical Trials

Innovation in Autoimmune and Bone Health Research: Driving Progress for Better Patient Outcomes

Worldwide Clinical Trials

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research

Research Clinical Trials Clinical Trials Immune Response

Scancell announces positive Phase 1 data for needle-free COVID-19 vaccines

BioPharma Reporter

FEBRUARY 13, 2023

Scancell has reported preliminary immunogenicity data from its Phase 1 COVIDITY clinical trial: with the plasmid DNA based COVID-19 vaccine candidates inducing immune responses when delivered via needle-free tech.

Immune Response

Immune Response Vaccination Vaccine DNA

Triggering tumor antiviral immune response in triple negative breast cancer

Scienmag

JANUARY 14, 2021

14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. HOUSTON – (Jan.

Immune Response

Immune Response RNA Medicine Research

Innovating in Autoimmune and Bone Health Research: Driving Progress for Better Patient Outcomes

Worldwide Clinical Trials

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research

Research Clinical Trials Clinical Trials Immune Response

COVID-19 vaccine development: Setback for Sanofi and GSK candidate, University of Queensland and CSL abandon trial

BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Immune Response

Immune Response Vaccination Vaccine Trials

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

Drug Discovery Today

APRIL 15, 2021

First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial the vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit). 176 volunteers will participate in the clinical trial the safety and immune response read-outs expected in Q2 2021

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Marburg virus vaccine shows promising results in first-in-human study

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination

Vaccination Vaccine Immune Response Allergies

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. “This trial will help us understand if we can use prototype and variant vaccines alone or together to shift immune responses to cover existing and emerging COVID-19 variants.”

Clinical Trials

Clinical Trials Clinical Trials Trials Immune Response

US FDA grants approval for Merck’s pneumococcal vaccine for children

Pharmaceutical Technology

JUNE 23, 2022

It was based on findings from seven double-blind, randomised, clinical trials that evaluated the safety, tolerability and immunogenicity of the vaccine in infants, children and adolescents.

Vaccination

Vaccination Vaccine Immune Response Clinical Trials

HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India

Pharmaceutical Technology

JUNE 30, 2022

At present, the vaccine is being analysed in clinical trials in the US, Brazil and South Korea. This technology can stimulate an immune response with a dose up to 20 times lower than current vaccines, which enhances safety, lowers costs, and increases production speed. .

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Sanofi/Translate start clinical trial of mRNA COVID shot

pharmaphorum

MARCH 12, 2021

Sanofi and Translate BIO have begun a clinical trial of their potential mRNA COVID-19 shot, as the French pharma struggles to keep pace with rivals despite its background in vaccines. A total of 415 healthy adults 18 years of age and older are expected to be enrolled in the trial across 13 investigational sites.

Clinical Trials

Clinical Trials Clinical Trials Trials Vaccine

Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council

The Pharma Data

DECEMBER 23, 2020

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. PARIS–( BUSINESS WIRE )– Inotrem S.A., Marc Derive. www.inotrem.com.

Clinical Trials

Clinical Trials Clinical Trials Trials Research

Moderna Vaccine Provokes Strong Immune Response in Children 6 to 11

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response

Immune Response Vaccination Vaccine Antibody

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. Source link.

Clinical Trials

Clinical Trials Clinical Trials Pharma Companies Vaccination

OncoResponse receives CPRIT grant to advance OR502

Pharmaceutical Technology

MAY 19, 2023

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials. It is planned to enter clinical studies this year.

Immune Response

Immune Response Clinical Trials Clinical Trials Antibody

Dual influenza & COVID-19 vaccine administration: Novavax announces positive results

BioPharma Reporter

JUNE 15, 2021

Co-administration of Novavaxâs COVID-19 vaccine candidate and an approved influenza vaccine induced robust immune responses, according to data from a clinical trial. âThe findings suggest simultaneous vaccination may be a viable immunization strategy,â says the company.

Vaccination

Vaccination Vaccine Immune Response Clinical Trials

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Exploring the Future of Oncology with ADCs and TILs: Key Insights From ASCO

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Check out this webinar on navigating the landscape of oncology clinical trials. Interested in hearing more insights from Matt?

Antibody

Antibody Clinical Trials Clinical Trials In-Vitro

Mix-and-match trial finds additional dose of COVID-19 vaccine safe, immunogenic

Scienmag

JANUARY 26, 2022

WHAT: In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA), an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The […]. (..)

Vaccination

Vaccination Vaccine Immune Response Trials

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

OCTOBER 14, 2022

The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccination

Vaccination Vaccine Development Immune Response

Therini Bio raises funds to develop neurodegenerative disease therapies

Pharmaceutical Technology

APRIL 28, 2023

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development

Development Immune Response Clinical Trials Clinical Trials

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

FEBRUARY 6, 2023

Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections. Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis.

Protein

Protein Research Antibody Immune Response

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Pharmaceutical Technology

AUGUST 15, 2022

The latest MHRA decision is based on findings from the Phase II/III clinical trial, where the mRNA-1273.214 vaccine met all primary endpoints. In baseline seronegative subjects, the updated vaccine offered a superior neutralising antibody response against Omicron (BA.1) 1) versus the 50µg mRNA-1273 booster dose.

Vaccination

Vaccination Vaccine Immune Response Clinical Trials

Vectura signs agreement to support the development of VR588 to treat asthma

Pharma Mirror

NOVEMBER 30, 2020

Pan-JAK inhibitors have been developed and tested in clinical trials, approved and commercialised for many different indications but mainly for the treatment of chronic inflammatory conditions associated with an overactive immune response.

Development

Development Immune Response Clinical Trials Clinical Trials

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

OCTOBER 6, 2022

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. .

Vaccination

Vaccination Vaccine Development Bacterium

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Gilead Sciences buys XinThera to boost oncology and inflammation pipeline

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. The acquisition will give Gilead Sciences access to XinThera’s portfolio of two small molecule inhibitor programmes, one of which targets PARP1 to treat cancer and the other of which targets MK2 for inflammatory diseases.

Immune Response

Immune Response DNA Clinical Trials Clinical Trials

COVID-19 vaccines may not produce sufficient antibody response in transplant recipients

Scienmag

MARCH 24, 2021

Department of Defense When clinical trials were conducted to determine the immunogenicity — the ability to elicit an immune response — for the first two vaccines marshaled against SARS-CoV-2the virus that causes COVID-19, one group was not among those included: people who have received solid organ […].

Immune Response

Immune Response Vaccine Vaccination Antibody

Amgen’s Tarlatamab Gets FDA Priority Review for Small Cell Lung Cancer

XTalks

DECEMBER 29, 2023

Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC). As a bispecific T-cell engager immunotherapy, tarlatamab directs the patient’s T cells to attack cancer cells exhibiting DLL3.

Clinical Trials

Clinical Trials Clinical Trials FDA Approval Trials

Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval

Pharmaceutical Technology

JUNE 10, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The vaccine works by inducing the body's immune response. Influenza vaccine 2 overview Vaccine is under development for the prevention of infections caused by pandemic influenza virus.

Production

Production Vaccination Vaccine Immune Response

Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval

Pharmaceutical Technology

JUNE 10, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The vaccine works by inducing the body's immune response. Influenza vaccine 2 overview Vaccine is under development for the prevention of infections caused by pandemic influenza virus.

Production

Production Vaccination Vaccine Immune Response

The Lancet Infectious Diseases: Preliminary results find vaccine candidate based on inactivated SARS-CoV-2 virus is safe and induces an immune response in healthy volunteers

Scienmag

OCTOBER 15, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate was carried out in China between 29 April and 30 July 2020 and involved more than 600 healthy volunteers.

Immune Response

Immune Response Vaccination Vaccine Clinical Trials

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

Trim the sugar: New HIV vaccine design improves immune response

Webinars

Trending Sources

Grand Rounds April 14, 2023: RECOVER in Action – Status of Clinical Trial Protocols (Kanecia Zimmerman, PhD, MD, MPH)

Webinars

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Clinical Trials for Celiac Disease: Insights from Beyond Celiac’s Kate Avery

Temperature-stable tuberculosis vaccine safe, prompts immune response in first-in-human trial

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

UK partners with BioNTech on clinical trials of mRNA cancer therapies

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma

Medicago Says COVID-19 Vaccine Candidate Triggers Promising Immune Response | 2020-11-10

Innovation in Autoimmune and Bone Health Research: Driving Progress for Better Patient Outcomes

Scancell announces positive Phase 1 data for needle-free COVID-19 vaccines

Triggering tumor antiviral immune response in triple negative breast cancer

Innovating in Autoimmune and Bone Health Research: Driving Progress for Better Patient Outcomes

COVID-19 vaccine development: Setback for Sanofi and GSK candidate, University of Queensland and CSL abandon trial

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

Marburg virus vaccine shows promising results in first-in-human study

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

US FDA grants approval for Merck’s pneumococcal vaccine for children

HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India

Sanofi/Translate start clinical trial of mRNA COVID shot

Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council

Moderna Vaccine Provokes Strong Immune Response in Children 6 to 11

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

OncoResponse receives CPRIT grant to advance OR502

Dual influenza & COVID-19 vaccine administration: Novavax announces positive results

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Exploring the Future of Oncology with ADCs and TILs: Key Insights From ASCO

Mix-and-match trial finds additional dose of COVID-19 vaccine safe, immunogenic

Merck and Moderna partner to develop and sell cancer vaccine

Therini Bio raises funds to develop neurodegenerative disease therapies

Feinstein Institutes researchers discover new protein for sepsis treatment

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Vectura signs agreement to support the development of VR588 to treat asthma

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

Gilead Sciences buys XinThera to boost oncology and inflammation pipeline

COVID-19 vaccines may not produce sufficient antibody response in transplant recipients

Amgen’s Tarlatamab Gets FDA Priority Review for Small Cell Lung Cancer

Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval

Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval

The Lancet Infectious Diseases: Preliminary results find vaccine candidate based on inactivated SARS-CoV-2 virus is safe and induces an immune response in healthy volunteers

Stay Connected